UBS Group’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.37M | Buy |
102,773
+10,344
| +11% | +$138K | ﹤0.01% | 4112 |
|
|
2025
Q1 | $942K | Sell |
92,429
-82,512
| -47% | -$841K | ﹤0.01% | 4226 |
|
|
2024
Q4 | $2.77M | Buy |
174,941
+119,034
| +213% | +$1.88M | ﹤0.01% | 3455 |
|
|
2024
Q3 | $3.25M | Sell |
55,907
-9,648
| -15% | -$560K | ﹤0.01% | 2637 |
|
|
2024
Q2 | $3M | Sell |
65,555
-58,630
| -47% | -$2.68M | ﹤0.01% | 2508 |
|
|
2024
Q1 | $8.22M | Sell |
124,185
-57,200
| -32% | -$3.79M | ﹤0.01% | 1751 |
|
|
2023
Q4 | $7.21M | Buy |
181,385
+174,798
| +2,654% | +$6.95M | ﹤0.01% | 1677 |
|
|
2023
Q3 | $210K | Sell |
6,587
-23,129
| -78% | -$737K | ﹤0.01% | 4240 |
|
|
2023
Q2 | $1.19M | Sell |
29,716
-3,335
| -10% | -$134K | ﹤0.01% | 3151 |
|
|
2023
Q1 | $1.41M | Sell |
33,051
-16,128
| -33% | -$689K | ﹤0.01% | 2893 |
|
|
2022
Q4 | $2.36M | Sell |
49,179
-114,060
| -70% | -$5.48M | ﹤0.01% | 2437 |
|
|
2022
Q3 | $6.14M | Sell |
163,239
-33,676
| -17% | -$1.27M | ﹤0.01% | 1579 |
|
|
2022
Q2 | $5.44M | Sell |
196,915
-2,768
| -1% | -$76.5K | ﹤0.01% | 1712 |
|
|
2022
Q1 | $10.9M | Buy |
199,683
+44,068
| +28% | +$2.4M | ﹤0.01% | 1406 |
|
|
2021
Q4 | $9.11M | Buy |
155,615
+25,833
| +20% | +$1.51M | ﹤0.01% | 1618 |
|
|
2021
Q3 | $5.14M | Buy |
129,782
+128,362
| +9,040% | +$5.08M | ﹤0.01% | 1976 |
|
|
2021
Q2 | $60K | Sell |
1,420
-14,147
| -91% | -$598K | ﹤0.01% | 5215 |
|
|
2021
Q1 | $958K | Buy |
15,567
+15,318
| +6,152% | +$943K | ﹤0.01% | 3406 |
|
|
2020
Q4 | $18K | Buy |
+249
| New | +$18K | ﹤0.01% | 5997 |
|
|
2020
Q3 | – | Sell |
-2,207
| Closed | -$83K | – | 7251 |
|
|
2020
Q2 | $83K | Buy |
+2,207
| New | +$83K | ﹤0.01% | 4618 |
|